Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced two new drug development candidates at its R&D day, held in New York.
The first candidate, RGLS5040, is an anti-miR targeting microRNA-27 (miR-27) for the treatment of cholestatic diseases. The second candidate, RGLS4326, is an anti-miR targeting microRNA-17 (miR-17) for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
"We are delighted to announce the addition of two new drug candidates to our growing portfolio of potential microRNA therapeutics. We believe both RGLS5040 and RGLS4326 have very favorable preclinical profiles with the potential to fulfill meaningful unmet medical needs," said Paul C Grint, M.D., president and chief executive officer of Regulus. "We are currently conducting IND-enabling work and finalizing development plans for RG5040 and RGLS4326 and expect to file INDs for both drug candidates in the second half of 2017. Today's announcement of two new drug development candidates underlines the confidence we have in our rigorous targeting and validation process, which we believe should enable us to identify at least one new drug development candidate per year moving forward."
Regulus Therapeutics Inc. is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs.